近端启动子中的天然调控突变通过创建新的GATA1位点升高胎儿珠蛋白表达
研究揭示-113A>G HPFH突变不同于该簇其他突变,不破坏BCL11A结合,而是创建GATA1激活因子结合位点;用CRISPR-Cas9将该突变引入红系细胞后GATA1结合增加、胎儿珠蛋白水平升高。
要点
- -113A>G HPFH突变不破坏BCL11A结合,而是创建新的GATA1结合位点。
- 用CRISPR-Cas9引入该突变可增加GATA1结合并升高胎儿珠蛋白水平。
- 胎儿珠蛋白启动子对创建激活因子新位点的点突变敏感。
核心结论
- -113A>G HPFH突变通过创建新的GATA1结合位点而非破坏BCL11A结合来升高胎儿珠蛋白。
- 胎儿珠蛋白启动子对点突变敏感,该突变创建了红系激活因子的新位点。
研究设计与样本
- 实验研究:将-113A>G HPFH突变用CRISPR-Cas9系统引入红系细胞。
主要发现
- -113A>G HPFH突变不破坏BCL11A结合,而是创建GATA1的从头结合位点。
- 用CRISPR-Cas9引入该突变后GATA1结合增加,胎儿珠蛋白水平升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-hemoglobinopathies, such as sickle cell disease and β-thalassemia, result from mutations in the adult β-globin gene. Reactivating the developmentally silenced fetal γ-globin gene elevates fetal hemoglobin levels and ameliorates symptoms of β-hemoglobinopathies. The continued expression of fetal γ-globin into adulthood occurs naturally in a genetic condition termed hereditary persistence of fetal hemoglobin (HPFH). Point mutations in the fetal γ-globin proximal promoter can cause HPFH. The -113A>G HPFH mutation falls within the -115 cluster of HPFH mutations, a binding site for the fetal globin repressor BCL11A. We demonstrate that the -113A>G HPFH mutation, unlike other mutations in the cluster, does not disrupt BCL11A binding but rather creates a de novo binding site for the transcriptional activator GATA1. Introduction of the -113A>G HPFH mutation into erythroid cells using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) system increases GATA1 binding and elevates fetal globin levels. These results reveal the mechanism by which the -113A>G HPFH mutation elevates fetal globin and demonstrate the sensitivity of the fetal globin promoter to point mutations that often disrupt repressor binding sites but here create a de novo site for an erythroid activator.
引用
- Martyn GE, Wienert B, Kurita R, et al. A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site. Blood. 2019. PMID: 30617196. doi:10.1182/blood-2018-07-863951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。